These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25131421)

  • 1. Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.
    Heselmeyer-Haddad KM; Berroa Garcia LY; Bradley A; Hernandez L; Hu Y; Habermann JK; Dumke C; Thorns C; Perner S; Pestova E; Burke C; Chowdhury SA; Schwartz R; Schäffer AA; Paris PL; Ried T
    Am J Pathol; 2014 Oct; 184(10):2671-86. PubMed ID: 25131421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
    Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
    Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.
    Yoshimoto M; Ding K; Sweet JM; Ludkovski O; Trottier G; Song KS; Joshua AM; Fleshner NE; Squire JA; Evans AJ
    Mod Pathol; 2013 Mar; 26(3):435-47. PubMed ID: 23018874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.
    Murphy SJ; Karnes RJ; Kosari F; Castellar BE; Kipp BR; Johnson SH; Terra S; Harris FR; Halling GC; Klein JL; Nasir A; Bergstrahl E; Rangel LJ; Sukov WR; Vasmatzis G; Cheville JC
    Mod Pathol; 2016 Feb; 29(2):143-56. PubMed ID: 26612463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
    Minner S; Lutz J; Hube-Magg C; Kluth M; Simon R; Höflmayer D; Burandt E; Tsourlakis MC; Sauter G; Büscheck F; Wilczak W; Steurer S; Schlomm T; Huland H; Graefen M; Haese A; Heinzer H; Jacobsen F; Hinsch A; Poos A; Oswald M; Rippe K; König R; Schroeder C
    Prostate; 2019 Feb; 79(3):302-311. PubMed ID: 30430607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.
    Reid AH; Attard G; Brewer D; Miranda S; Riisnaes R; Clark J; Hylands L; Merson S; Vergis R; Jameson C; Høyer S; Sørenson KD; Borre M; Jones C; de Bono JS; Cooper CS
    Mod Pathol; 2012 Jun; 25(6):902-10. PubMed ID: 22460813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
    Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
    Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
    Furusato B; Gao CL; Ravindranath L; Chen Y; Cullen J; McLeod DG; Dobi A; Srivastava S; Petrovics G; Sesterhenn IA
    Mod Pathol; 2008 Feb; 21(2):67-75. PubMed ID: 18065961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.
    Chaux A; Albadine R; Toubaji A; Hicks J; Meeker A; Platz EA; De Marzo AM; Netto GJ
    Am J Surg Pathol; 2011 Jul; 35(7):1014-20. PubMed ID: 21677539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.
    Grupp K; Roettger L; Kluth M; Hube-Magg C; Simon R; Lebok P; Minner S; Tsourlakis MC; Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Wilczak W; Huland H; Schlomm T; Steurer S; Krech T
    Oncol Rep; 2015 Sep; 34(3):1211-20. PubMed ID: 26134445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
    Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.
    Krohn A; Freudenthaler F; Harasimowicz S; Kluth M; Fuchs S; Burkhardt L; Stahl P; C Tsourlakis M; Bauer M; Tennstedt P; Graefen M; Steurer S; Sirma H; Sauter G; Schlomm T; Simon R; Minner S
    Mod Pathol; 2014 Dec; 27(12):1612-20. PubMed ID: 24762546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.
    Fisher KW; Zhang S; Wang M; Montironi R; Wang L; Baldrige LA; Wang JY; MacLennan GT; Williamson SR; Lopez-Beltran A; Cheng L
    Mol Carcinog; 2017 Mar; 56(3):814-820. PubMed ID: 27500376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
    Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
    Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
    Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
    Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of PTEN alterations, TMPRSS2-ERG fusion and their association in prostate cancer.
    Fallahabadi ZR; Noori Daloii MR; Mahdian R; Behjati F; Shokrgozar MA; Abolhasani M; Asgari M; Shahrokh H
    Gene; 2016 Jan; 575(2 Pt 3):755-60. PubMed ID: 26424596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma.
    Albadine R; Latour M; Toubaji A; Haffner M; Isaacs WB; A Platz E; Meeker AK; Demarzo AM; Epstein JI; Netto GJ
    Mod Pathol; 2009 Nov; 22(11):1415-22. PubMed ID: 19734849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence.
    Qu X; Jeldres C; Glaskova L; Friedman C; Schroeder S; Nelson PS; Porter C; Fang M
    J Mol Diagn; 2016 Mar; 18(2):215-24. PubMed ID: 26752304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
    Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
    Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.